Drug Database
AN

anti-tetanus immunoglobulin (Tetglob)

✓ Approved

Bharat Serums and Vaccines Limited · therapeutic agent

What is anti-tetanus immunoglobulin?

anti-tetanus immunoglobulin is a therapeutic agent developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesTetglob
CompanyBharat Serums and Vaccines Limited
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved

Therapeutic Indications

anti-tetanus immunoglobulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedJPGN reports2026-11-11

A real-world comparison of celiac tissue transglutaminase immunoglobulin A antibody levels in pediatric patients using two different diagnostic kits.

Kori Michal M, Guz-Mark Anat A, Perets Tsachi Tsadok TT, Davidpur Amit A et al.

Pediatric celiac disease (CeD) may be diagnosed without a biopsy when tissue-transglutaminase (TTG) immunoglobulin A (IgA) antibodies are ≥10x the upper limit of normal (ULN) and anti-endomysial antibodies are positive in a second sample. The no-biopsy diagnosis demands a very high accuracy and reliability of the TTG diagnostic kits. Inter-assay differences may affect category classification. We compared TTG-IgA levels performed by two reliable kits: Bioplex 2200 and Liaison-XL in routine care. Using the Clalit Health Services database, we identified pediatric patients with paired TTG-IgA measurements from both kits within ≤14 days. Values were expressed as multiples of ULN and categorized: 10x ULN. Agreement was assessed for ≤7 and ≤14-day windows using Cohen's ĸ. Category discordance occurred in 17.4% (109/625) of paired tests within 14 days and 11.8% (38/321) within 7 days. Overall agreement was substantial (ĸ = 0.62 for 14 days; ĸ = 0.63 for 7 days). Concordance was high for negative results (96.0%), but significantly lower for the critical >10x ULN threshold at 14 days (88.2%, p = 0.009). Significant discordance between these two reliable TTG-IgA kits at 14 days, exceeding 10% in the >10x ULN category, warrants careful consideration when using the no-biopsy approach for CeD diagnosis, as assay choice may impact clinical classification.

PubMedEuropean journal of case reports in internal medicine2026-11-11

Triple-Positive Antiphospholipid Syndrome with Splenic Infarction Triggered by Tocilizumab Withdrawal in A High-Titer ACPA-Positive Rheumatoid Arthritis Patient: An Unmasking Storm of Polyautoimmunity.

Coviello Francesco Elios FE, Rotondo Cinzia C, D'Onofrio Francesca F, Barile Raffaele R et al.

We describe the occurrence of an uncommon thrombotic event, namely splenic infarction, as the onset of antiphospholipid syndrome (APS) after temporary suspension of anti-IL-6 treatment in a patient with rheumatoid arthritis (RA). A 53-year-old patient with anti-citrullinated protein antibody (ACPA) and rheumatoid factor-positive RA, previously showing transient positivity for immunoglobulin (Ig)G anticardiolipin antibodies and lupus anticoagulant (LAC), refractory to multiple biological disease-modifying anti-rheumatic drugs (DMARDs), anti-tumour necrosis factor (TNF)-α agents, and rituximab, had been treated with tocilizumab since 2013 with good clinical response. After temporary suspension of tocilizumab for minor orthopaedic surgery complicated by skin abscess, he developed acute abdominal pain and computed tomography evidence of splenic infarction. Laboratory evaluation revealed elevated inflammatory markers and triple positivity for LAC, aCL IgG, and aB2GPI IgG, leading to the diagnosis of APS. Treatment with warfarin, methotrexate, and baricitinib resulted in stable disease control without recurrent thrombotic events. Clinical stability in RA is a delicate balance between control of inflammation and avoidance of medication toxicity, especially in patients with high thrombotic risk and previous antiphospholipid positivity. Temporary withdrawal of biologic therapy may induce immunological rebound and thrombotic complications. This case highlights the importance of thrombotic risk stratification and multidisciplinary management when biologic therapies are suspended. Tocilizumab may act as a suppressor of autoreactive B-cell clones producing antiphospholipid antibodies.A high anti-citrullinated protein antibody (ACPA) titer may be associated with an increased risk of developing autoantibody storm with possible prothrombotic complications in rheumatoid arthritis, such as antiphospholipid syndrome.In case of surgical interventions in patients with rheumatoid arthritis treated with biological disease-modifying anti-rheumatic drugs (bDMARDs) it is important to evaluate the stratification of thrombotic risk with multidisciplinary discussion before suspending therapy.

PubMedEuropean heart journal. Case reports2026-11-11

Anti-Ku myositis presenting with progressive inflammatory myocarditis: diagnostic pitfalls in a fatal case-case report.

ELBekiey Ahmed A, Zhlawi Mohamed Wahib MW, Tong Jie J, Roy Debashis D et al.

Anti-Ku antibodies are rare disease of overlap myositis and often signal multisystem involvement. Overt heart failure, however, is seldom reported. A 60-year-old man presented with progressive exertional dyspnoea and chest tightness. Initial echocardiography showed mildly reduced left ventricular ejection fraction (LVEF 49%), and coronary angiography was normal, leading to a diagnosis of MINOCA. One month later, he re-presented with worsening breathlessness, dysphagia, and proximal muscle weakness. Laboratory tests revealed serum creatine kinase 2154-2680 IU/L, troponin 1437 ng/L, and pro-BNP 3290 ng/L. Repeat echocardiography demonstrated dilated ventricles and LVEF 35%. During admission, he developed high-grade AV dissociation requiring dual-chamber pacing and abrupt thrombocytopenia. Cardiac MRI identified a diffuse infiltrative pattern with LVEF 18%. Myositis-specific immunoblot detected high-titre anti-Ku antibodies, and deltoid biopsy confirmed inflammatory myopathy. Despite high-dose corticosteroids, mycophenolate, cyclophosphamide, rituximab and intravenous immunoglobulin, cardiac function deteriorated to LVEF 12%. Recurrent aspiration pneumonia necessitated gastrostomy. Eight months after initial presentation, the patient died following transition to palliative care. This case highlights the danger of assuming that an elevated troponin level is equivalent to myocardial infarction. Non-dynamic troponin elevation with global LV dysfunction and non-obstructive coronaries indicates myocardial injury and warrants investigation for inflammatory and other non-ischaemic causes. Systemic 'red flags' such as dysphagia must trigger early multidisciplinary evaluation to avoid fatal diagnostic delay.

PubMedAnalytical chemistry2026-11-11

One-step immunoassay for Interleukin-4 (IL4) Detection Using IL4-Receptor Mimotopes Screened from Fv-Antibody Library.

Kwon Soonil S, Jung Jaeyong J, Sung Jeong Soo JS, Bae Hyung Eun HE et al.

One-step immunoassay for IL4 was developed using a hypervariable part of immunoglobulin G (Fv-antibody) and switching-peptides. Conventional immunoassays require multistep procedures, whereas one-step immunoassays do not require additional steps. Fv-antibodies comprise three complementarity-determining regions (CDRs) and three frame regions (FRs). An Fv-antibody library was constructed using site-directed mutagenesis of the CDR3 region (with 11 amino acid residues) and expressed on the outer membrane of Escherichia coliusing autodisplay technology. Two IL4 receptor (IL4r) mimotopes, designated Fv-1 and Fv-2, were screened from the Fv-antibody library using the anti-IL4r antibody. These mimotopes were expressed as soluble proteins with three CDRs and four FRs. Using the surface plasmon resonance (SPR) biosensor, the binding affinities of the mimotopes Fv-1 and Fv-2 to the anti-IL4r antibody were 39.5 and 48.8 nM, respectively. Using HEK-Blue IL4 cells, the expressed IL4r mimotopes were analyzed to determine whether they compete with IL4r for the binding of IL4. The inhibition constants of mimotopes were 2.3 and 1.9 μM for Fv-1 and Fv-2, respectively. The interaction between mimotopes and IL4r (binding affinity and amino acids) was analyzed and compared with that of IL4 using a docking simulation. The interaction between mimotopes and IL4 occurred at binding sites on IL4r. A complex of expressed mimotopes and switching-peptides (fluorescence-labeled) was used for detecting IL4. The binding of IL4 to the complex resulted in the quantitative release of switching-peptides. IL4 detection was within the clinically required IL4 concentration range.

PubMedInternational journal of endocrinology2026-11-11

Prevalence of Celiac Disease in Children and Adolescents With Type 1 Diabetes in Saudi Arabia: A 20-Year Experience in a Tertiary Care Center.

AlShaikh Adnan A, Alghamdi Abdulaziz A, Alshaikh Sahl S, Almatihmy Yahya Y et al.

Variable rates of co-occurrence of celiac disease (CD) and Type 1 diabetes mellitus (T1DM) in the pediatric population have been reported across numerous studies. This retrospective study aimed to determine the prevalence of CD and other autoimmune disorders in children and adolescents (1 to 18 years) from Saudi Arabia with T1DM at King Abdulaziz Medical City-Jeddah. Additionally, we assessed the specificity and sensitivity of different CD serological diagnostic tests. A total of 595 children and adolescents with T1DM were included in the study. Positive CD serological tests were reported in 9.4% and positive biopsy in 5.4%. Duodenal biopsy confirmed CD in 62.5% of children and adolescents with positive tissue transglutaminase immunoglobulin A (IgA), 65.6% with positive endomysia antibodies, and 46.9% with positive anti-gliadin antibodies. The tissue transglutaminase IgA test at diagnosis demonstrated the highest specificity (91%), while the anti-gliadin antibody IgA test exhibited the highest sensitivity (68.2%). Children and adolescents with diabetes and CD exhibited a significantly higher prevalence of Hashimoto's thyroiditis (18.8%) compared to those without CD (8.3%). No significant differences were observed in anthropometric parameters between the two groups. However, children and adolescents with both diseases demonstrated higher hemoglobin A1c levels and more frequent occurrence of episodes of ketoacidosis and hypoglycemia. These glycemic abnormalities may be attributed to the carbohydrate content of gluten-free (GF) foods and/or poor compliance with GF diets, leading to nutrient malabsorption. A precise diagnosis of CD through serological testing, selected endoscopic evaluation, and dietary control, including accurate carbohydrate counting in GF foods along with adjustments in prandial insulin doses, can significantly enhance glycemic control in these patients.

PubMedCureus2026-11-11

Intestinal Paracoccidioidomycosis Masquerading as Crohn's Disease: Diagnostic Pitfalls in a Case Report.

Cerqueira Ana A, Seco Tiago T, Moniz Joana J, Lemos Bárbara B et al.

Paracoccidioidomycosis (PCM) is a systemic fungal infection caused by Paracoccidioides spp., predominantly found in Brazil. It primarily affects the respiratory system, while extrapulmonary involvement is rare. Disseminated PCM in immunocompetent hosts may be associated with exposure burden, host factors, delayed diagnosis, and disease phenotype. We present the case of a 28-year-old Brazilian man who had been living in Portugal for five months and presented to the emergency department with persistent abdominal pain lasting three weeks. Initial evaluation revealed mesenteric lymph-node conglomerates. During hospitalization, an extensive workup was performed, including screening for active neoplastic disease, immunosuppressive states, and active infection. A fourth-generation HIV combined antigen/antibody test was negative. Immunoglobulin levels were within the normal range (immunoglobulin A 160 mg/dL, immunoglobulin M 200 mg/dL and immunoglobulin G 1500 mg/dL). There was no history of immunosuppressive medication use including steroid or biologic, and no history of diabetes or transplantation. There was also no clinical or imaging evidence of solid or haematological malignancy. Immunophenotyping of peripheral blood and two lymph nodes showed no changes of pathological significance. Clinical, imaging, endoscopic, and histologic findings suggested Crohn's disease, although the presentation was atypical because of the extent of painful lymphadenopathy and hepatosplenomegaly. However, Periodic Acid-Schiff (PAS) and Ziehl-Neelsen staining were performed on the initial slides containing granulomas (inguinal lymph node and samples from the ileum and colon, but did not demonstrate evidence of infection at that time). A trial with high-dose corticosteroids was initiated.  Following subsequent deterioration, an axillary lymph-node was excised. Gomori-Grocott (GG) staining, which was only performed at this stage, revealed the "ship's pilot wheel" appearance. There was no isolation in cultures and serologic and polymerase chain reaction (PCR) testing for Paracoccidioides spp. could not be performed at our hospital. Therefore, the diagnosis of paracoccidioidomycosis was established based on histologic morphology, epidemiologic context, and suggestive clinical features. After the diagnosis was established, the initial slides were reviewed and GG staining was added, becoming clear that the fungal forms were already present in all the tested samples, but had gone unrecognized. Imported fungal infections in non-endemic areas present significant clinical challenges, including delayed diagnosis and limited clinician experience. In Portugal, only one private laboratory can perform PCR and serologic testing for paracoccidioidomycosis. This limitation highlights an important lesson from this case: a diagnosis cannot be made if the disease is not considered. This case may therefore serve as a useful resource for settings with similar diagnostic limitations. Given the extreme rarity of extrapulmonary PCM, this case highlights the need for a comprehensive diagnostic approach to intestinal granulomatous diseases, particularly in patients from endemic regions, and emphasizes the role of internal medicine in this diagnostic process.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-tetanus immunoglobulin